Live data from Hacker News

Launch YC S21: Meet the Batch, Thread #6

news.ycombinator.com

81–90 of 120 posts

Re: Launch YC S21: Meet the Batch, Thread #6

#81
post #79
post #2

Hey HN, I’m Etai, together with Andrew a co-founder of Secoda ( https://www.secoda.co ). Secoda is a collaborative workspace for data teams that makes it easy to share metadata, queries, charts and documentation with any employee. Companies store a growing amount of knowledge in BI tools, data warehouses, data pipelines, queries and documentation. Because these tools are not connected, it has become more difficult to…

You mention data lineage on your pricing page, but do you have any examples of what that looks like? Can you support custom lineages driven by an api?

An example of what lineage would look like is the following: You have source tables A and B that are joined to create a model C and then C is used in dashboard D. We are able to infer the lineage A->C->D and B->C->D.

We extract lineage in a couple of different ways. The main way is by parsing SQL queries in your data warehouse to determine which tables and dashboards are upstream/downstream. The other way we extract lineage information provided directly from dbt and BigQuery who have nice APIs for this information.

We are working releasing an API in Q4 that supports pushing information from say an Airflow DAG to Secoda to give us more lineage context. Hopefully this answers your questions.

Re: Launch YC S21: Meet the Batch, Thread #6

#82
post #5

Hey everyone! We’re Juliana and Robert, co-founders of Parallel Bio. We're improving drug discovery by replacing animal models, in the hope of making cures for humans, not mice. The biggest reason why 92% of new drugs fail is that drugs are currently discovered in mice, which are not realistic models of human disease but are used due to the challenges of working in humans. We've created a human ‘immune system in a di…

Heads up I went to email you a congratulatory email at hello@parallel.bio but my email was rejected. Might want to double check your google groups settings.

Re: Launch YC S21: Meet the Batch, Thread #6

#83

This is Chris and Robert from HeyCharge ( https://heycharge.io/ ). We're developing low-cost EV charging for indoor environments like underground parking garages. Current indoor EV chargers are expensive to buy, install, and operate, especially because they need internet connections and cloud-based backends. They're also unreliable, because even if the charger's internet connection works, the user might not have one…

EV charging in shared use / multi-family housing is still one of the harder areas to solve. So great to see more options coming - I wish you the best of luck. One side is also regulatory. At least where I was because the building feed was not up to code, and to get charging in would hit meters, the upgrade costs were too high. Hopefully solutions can show up there as well. Love not having to have network connectivity…

[deleted]

Re: Launch YC S21: Meet the Batch, Thread #6

#84

This is Chris and Robert from HeyCharge ( https://heycharge.io/ ). We're developing low-cost EV charging for indoor environments like underground parking garages. Current indoor EV chargers are expensive to buy, install, and operate, especially because they need internet connections and cloud-based backends. They're also unreliable, because even if the charger's internet connection works, the user might not have one…

EV charging in shared use / multi-family housing is still one of the harder areas to solve. So great to see more options coming - I wish you the best of luck. One side is also regulatory. At least where I was because the building feed was not up to code, and to get charging in would hit meters, the upgrade costs were too high. Hopefully solutions can show up there as well. Love not having to have network connectivity…

We aren't able to fix every wiring or capacity issue in every building, but we have a neat combination of low-power hardware options and load management. The net effect is that often our infrastructure will work where other options struggle. And thank you for the kind wordsa

Re: Launch YC S21: Meet the Batch, Thread #6

#85

This is Chris and Robert from HeyCharge ( https://heycharge.io/ ). We're developing low-cost EV charging for indoor environments like underground parking garages. Current indoor EV chargers are expensive to buy, install, and operate, especially because they need internet connections and cloud-based backends. They're also unreliable, because even if the charger's internet connection works, the user might not have one…

Hi Chris and Robert. I'm the cofounder of Smartcar.com. We're an API for EVs. We're backed by a16z and NEA. (I also went to UC Davis too!) I'm excited about what you folks are doing and would love to connect. We've been helping many companies in this space better integrate with electric cars. Can you shoot me an email? sahas@smartcar.com

Will certainly drop you a line! Thanks for reaching out!

Re: Launch YC S21: Meet the Batch, Thread #6

#86
post #7

Hi there! We are Orestis and Urs from Zeit Medical ( https://www.zeitmedical.com ). We enable fast stroke detection at home. 90% of strokes go untreated due to stroke recognition delays. Many patients live in fear that a stroke might happen and go unnoticed for hours, particularly if they are asleep when it starts. Stroke is currently impossible to detect based on symptoms. Unlike a heart attack, there is no distinct…

Looks amazing!

Your website also mentions seizures. Are you trying to get FDA clearance for both?

Also, why did you choose the subscription route?

Re: Launch YC S21: Meet the Batch, Thread #6

#87

Earlier quoted context omitted.

I always try to reverse a situation to see if it makes sense, and then I ask myself: what would we think if aliens came to earth to experiment on us with untested medicine, kill us afterwards and only when it is perfectly safe on us they would apply it to themselves. I believe a large fraction of humanity would say that that is unethical and they'd have all kinds of cognitive dissonance to deal with (and associated r…

We feel exactly the same way. Not only is it unacceptable that over 110 million animals a year are sacrificed for research, but these models do a terrible job of translating to humans and in most cases cannot even model the disease of interest but are used regardless. I used to work in tuberculosis where mice are predominantly used even though they do not get the disease and the disease they do get has the exact oppo…

If it's ok with you I will point some investors in your direction that are doing deals in this space.

Re: Launch YC S21: Meet the Batch, Thread #6

#88
post #6

We are the founders of Kodex ( https://www.kodex.us ). Kodex makes it easy for companies to process and respond to subpoenas from governments around the world. Government agencies subpoena user data from thousands of companies around the world, and companies largely rely on email, fax, and spreadsheets to manage them. At a previous job, we would frequently see companies struggle to comply with legal orders, because t…

Congrats on the launch.

What's the hardest thing you have found getting Kodex to this point?

How many government bodies are you connected to? Can you use your platform even if they do not use it?

Do you use a subscription pricing model?

Re: Launch YC S21: Meet the Batch, Thread #6

#89
post #5

Hey everyone! We’re Juliana and Robert, co-founders of Parallel Bio. We're improving drug discovery by replacing animal models, in the hope of making cures for humans, not mice. The biggest reason why 92% of new drugs fail is that drugs are currently discovered in mice, which are not realistic models of human disease but are used due to the challenges of working in humans. We've created a human ‘immune system in a di…

Amazing and very cool! A couple of questions, if you can share at this time, since this resonates with my interests.

- Which patient/donor cell type are these immune organoids derived from?

- Are the organoids made with induced pluripotent stem cell technology?

- What is part of the workup post treatment, e.g. histology, NGS? If NGS, what kind (WGS, WES, RNASeq) and technologies (Illumina, PacBio, ONT)?

- Are you looking for mutations from the drug and vaccine treatment (e.g. comet assay, Duplex-Seq)?

Re: Launch YC S21: Meet the Batch, Thread #6

#90

Earlier quoted context omitted.

We feel exactly the same way. Not only is it unacceptable that over 110 million animals a year are sacrificed for research, but these models do a terrible job of translating to humans and in most cases cannot even model the disease of interest but are used regardless. I used to work in tuberculosis where mice are predominantly used even though they do not get the disease and the disease they do get has the exact oppo…

If it's ok with you I will point some investors in your direction that are doing deals in this space.

Please do, and I appreciate the introductions! My email is robert at parallel.bio.
Post reply on HN